ACW · ASX

Actinogen Medical Limited (ASX:ACW)

AU$0.026

 -0.001 (-3.704%)
ASX:Live
09/05/2025 03:50:19 PM
HALO Ords HALO Earnings Momentum GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ACW Overview

ACW Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Weak

Growth

Earnings

Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ACW

Website

Actinogen Medical Limited

Telephone

61.2.8964.7401

Address

Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000

Description

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.

ACW Price Chart

Key Stats

Market Cap

AU$79.43M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.1

Trade Value (12mth)

AU$76,046.00

1 week

3.85%

1 month

0%

YTD

3.85%

1 year

-10%

All time high

0.84

Key Fundamentals

EPS 3 yr Growth

130.80%

EBITDA Margin

N/A

Operating Cashflow

-$17m

Free Cash Flow Return

-101.60%

ROIC

-78.20%

Interest Coverage

-937.40

Quick Ratio

13.90

Other Data

Shares on Issue (Fully Dilluted)

2917m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACW Announcements

Latest Announcements

Date Announcements

30 April 25

Actinogen March 2025 quarterly activity report & Appendix 4C

×

Actinogen March 2025 quarterly activity report & Appendix 4C

24 April 25

ACW Science Forum notice - Preparing for commercialization

×

ACW Science Forum notice - Preparing for commercialization

23 April 25

Change in substantial holding

×

Change in substantial holding

02 April 25

ACW CMO presents Xanamem pTau poster at ADPD25 conference

×

ACW CMO presents Xanamem pTau poster at ADPD25 conference

27 March 25

ACW conducts Type C meeting with FDA regarding depression

×

ACW conducts Type C meeting with FDA regarding depression

26 March 25

Actinogen presentation to ASX small & mid-caps conference

×

Actinogen presentation to ASX small & mid-caps conference

24 March 25

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

24 March 25

Notification of cessation of securities - ACW

×

Notification of cessation of securities - ACW

24 March 25

Notification of cessation of securities - ACW

×

Notification of cessation of securities - ACW

24 March 25

Appendix 3Ys x 5

×

Appendix 3Ys x 5

14 March 25

Results of Meeting

×

Results of Meeting

04 March 25

Notification of buy-back - ACW

×

Notification of buy-back - ACW

24 February 25

Actinogen HY2025 financial report and Appendix 4D

×

Actinogen HY2025 financial report and Appendix 4D

24 February 25

ACW HY25 results Advancing to latestage clinical development

×

ACW HY25 results Advancing to latestage clinical development

10 February 25

Letter to Shareholders, Notice of GM & Proxy Form

×

Letter to Shareholders, Notice of GM & Proxy Form

06 February 25

Peer-reviewed clinpharm manuscript published

×

Peer-reviewed clinpharm manuscript published

30 January 25

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

29 January 25

ACW December 2024 quarterly activity report & Appendix 4C

×

ACW December 2024 quarterly activity report & Appendix 4C

13 January 25

ACW presents at Sachs Neuro & WHO grants INN emestedastat

×

ACW presents at Sachs Neuro & WHO grants INN emestedastat

19 December 24

Change in substantial holding

×

Change in substantial holding

16 December 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

13 December 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

13 December 24

Listed Options Top 20 & Distribution Schedule

×

Listed Options Top 20 & Distribution Schedule

13 December 24

ACW to list $0.05 options exp 31 May 2027 - ASX code ACWOD

×

ACW to list $0.05 options exp 31 May 2027 - ASX code ACWOD

09 December 24

ACW randomizes first US participant in Alzheimers trial

×

ACW randomizes first US participant in Alzheimers trial

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACW Shortsell

Frequently Asked Questions

The current share price of Actinogen Medical Limited (ACW:ASX) is AU$0.026.
The 52-week high share price for Actinogen Medical Limited (ACW:ASX) is AU$0.10.
The 52-week low share price for Actinogen Medical Limited (ACW:ASX)? is AU$0.02.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) has a franking level of 0.0%.
Actinogen Medical Limited (ACW:ASX) is classified in the Healthcare.
The current P/E ratio for Actinogen Medical Limited (ACW:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.